CARB-X Application Round #3 goes live!

Dear All:

The wait is over — CARB-X has today released a call for new applications! The call has an interesting 2-round structure and you’ll need to study carefully both the press release and the supplemental details document to understand where your program would fit. Here’s my summary:

  • Round 1:
    • Submission window for Expressions of Interest: 22-29 March 2018
    • Scope: Restricted to new classes of direct-acting small molecule and large molecule antibacterials that have potential to cover the top 6 Gram-negative pathogen groups from the WHO and CDC priority listsA. baumannii (carbapenem-R), P. aeruginosa (carbapenem-R), Enterobacteriaceae (carbapenem-R and/or 3rd-gen ceph-R), Salmonellae spp. (fluoroquinolone-R), N. gonorrhoeae (3rd-gen ceph-R, fluoroquinolone-R), and Shigella spp. (fluoroquinolone-R).
  • Round 2:
    • Submission window for Expressions of Interest: 1-8 June 2018
    • Scope: Both direct- and indirect-acting therapeutics as well as vaccines, diagnostics and devices that meet certain criteria.
    • In terms of therapeutics, both novel and known classes are acceptable.

The very tight focus of Round #1 feels right to me … we really need to push hard at a global level on the creation of entirely novel classes of direct-acting agents. These will be rare but they are needed.

The scope of Round #2 is then broad and roughly comparable to the scope of prior CARB-X funding rounds.

With an announced portfolio of more than 20 projects and its search for both new accelerators and new staff, CARB-X continues to lead the charge against AMR. Exciting times! 

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: http://amr.solutions/blog/

Upcoming meetings of interest to the AMR community:

Share

17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top